RT期刊文章SR电子T1双氢麦角胺:回顾产妇在怀孕期间接触(P03.108)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P03.108 OP P03.108 VO 80是7补充A1西尔伯首页斯坦(Stephen A1 Shashidhar古里A1黎明Buse A1黎明马库斯A1椎名极光A1格雷琴Tietjen A1 > - A1安德鲁Czeizel A1 Richard Lipton年2013 UL //www.ez-admanager.com/content/80/7_Supplement/P03.108.abstract AB目的:评估潜在风险进行文献综述与母亲接触双氢麦角胺(她)怀孕期间。背景:怀孕风险类别药物分配给我们基于来自动物和人类研究的证据。当前配方的她和麦角胺有相同的怀孕风险类别(X),尽管她更少的血管和子宫的影响。设计/方法:MEDLINE / PubMed搜索进行了识别引用从1945年1月至2011年10月出版,描述胎儿与她在怀孕期间或麦角胺使用相关的结果。包括临床研究,病例报告/系列、数据库/回顾评论或研究,文章通过二次确定搜索相关文章和引用,包括主要作者。综述了研究设计、治疗干预措施和结果。结果:213个潜在的引文,11满足入选标准。胎儿的结果数据> 350婴儿暴露在子宫内没有显示主要先天畸形的风险显著增加。早产的风险增加了,然而,已经被报道。瞬态胎儿心动过缓也当她是报道中使用劳动力。增加流产的风险可能是静脉注射高剂量诱导劳动有关。CONCLUSIONS: In this literature analysis, DHE use during pregnancy was not reported to be associated with a statistically significant risk of major congenital malformations. It was however associated with a higher risk of prematurity.Supported by: MAP Pharmaceuticals, Inc.Disclosure: Dr. Silberstein has received personal compensation for activities with Allergan, Amgen, Capnia, Coherex, Iroko Pharmaceuticals, Lilly, MAP, Medtronic, Neuralieve, NINDS, NuPathe, Pfizer, St. Jude Medical as an advisory board member and from Amgen, Nautiluss, Opti-Nose, and Zogenix as a consultant. Dr. Silberstein has received personal compensation in an editorial capacity for Current Pain and Headache Reports and Medlink as an advisory board member. Dr. Silbertsein has received research support from Allergan, BMS, Cumberland, Lilly, MAP, Merck, OptiNose, and St. Jude Medical. Dr. Kori has received personal compensation for activities with MAP Pharmaceuticals, Inc. Dr. Kori holds stock and/or stock options in MAP Pharmaceuticals, Inc. Dr. Kori has received research support from MAP Pharmaceuticals, Inc. Dr. Buse has received personal compensation for activities with Allergan as a scientific advisor. Dr. Buse has received research suprrot or has support pending from Allergan, ENDO, MAP, Nupathe and Merck to the National Headache Foundation. Dr. Marcus has received research support from Pfizer Inc, Merck & Co., Inc., and GlaxoSmithKline, Inc. Dr. Aurora has received personal compensation for activities with GlaxoSmithKline, Inc., Merck & Co., Inc., Ortho-McNeil, Allergan, Inc., MAP Pharmaceuticals, Kyowa, and Neuraleve. Dr. Aurora has received research support from Alexza, Allergan, Inc., GlaxoSmithKline, Inc., Merck, Pfizer, Inc., Ortho-McNeil, MAP pharmaceuticals, Takeda, and Neuraleve. Dr. Tietjen has received personal compensation for activities with MAPP. Dr. Tietjen holds stock and/or stock options in Johnson & Johnson and Stryker. Dr. Tietjen's institution received research support from Lundbeck Research USA, inc. Dr. Berard has received personal compensation for activities with MAP Pharmaceuticals. Dr. Berard has received research support from MAP Pharmaceuticals, CIHR, FRSQ, and NIH. Dr. Czeizel has nothing to disclose. Dr Lipton has received personal compensation for activities with Allergan, Inc., Boston Scientific, Bristol-Myers Squibb Company, Cognimed, Colucid, Eli Lilly & Company, eNeura Therapeutics, GlaxoSmithKline, Inc., MAP, Merck, Nautilus Neuroscience, Novartis, and NuPathe. Dr. Lipton holds stock and/or stock options in eNeura Therapeutics.Tuesday, March 19 2013, 2:00 pm-6:30 pm